Biotech and Pharmaceuticals Life Sciences

More

  • NEW YORK, Feb 26- Modern cancer drugs supercharge immune systems, target specific gene mutations and pack modified viruses into vaccines. The Knoxville, Tennessee, company reported promising results in a small melanoma study. The company must replicate its early results on a bigger scale, and a U.S. Food and Drug Administration decision is not expected before...

  • Feb 17- Hopes of developing a vaccine against Zika took a small step forward on Wednesday as Inovio Pharmaceuticals Inc said its experimental shot had induced a robust and durable response in mice. At least 15 companies and academic groups are currently racing to develop Zika vaccines, according to the World Health Organization, spurred on by growing public...

  • Feb 15- Biopharmaceutical company Amgen Inc said on Monday its Aranesp drug met its primary goal of reducing the incidence of red blood cell transfusions in anemic patients suffering from Myelodysplastic Syndromes in a phase 3 trial. Amgen last year reached a $71 million settlement with 48 U.S. states and the District of Columbia to resolve claims that it...

  • 2015 has been a fantasic year: Actelion CEO

    Jean-Paul Clozel, CEO of Actelion, says 2015 may be the company's best year, with sales crossing 2 billion Swiss francs thanks to the drug Opsumit.

  • NEW YORK, Feb 3- Former pharmaceutical executive Martin Shkreli suffered a roughly $40 million drop in the value of a trading account used to secure his bail following his arrest on securities fraud charges, a U.S. prosecutor said on Wednesday. That caused the value of Shkreli's E* Trade brokerage account to drop to $4 million to $5 million, from the $45 million...

  • LONDON, Feb 3- The world is once again asking scientists and drugmakers to come up rapidly with a vaccine for a viral disease that, in the latest case, few people had heard of until a few weeks ago, and even fewer feared. Making a shot to generate an immune response against Zika virus, which is sweeping through the Americas, shouldn't be too hard in theory.

  • *Assembles eight-person team to look into practicalities. *Will reach conclusion on how to proceed in next few weeks. LONDON, Feb 3- Japan's leading drugmaker Takeda Pharmaceutical is investigating ways in which it might help make a Zika vaccine, becoming the latest company to study vaccine options for the mosquito-borne disease sweeping the Americas.

  • ChemChina to buy Sygenta for $43 billion

    CNBC's Julia Chatterley reports from Basel on Syngenta and the takeover deal by ChemChina, a Chinese state-owned company.

  • GENEVA/ PARIS, Feb 2- The Zika virus could spread to Africa, Asia and southern Europe, the World Health Organization said on Tuesday, as major French drugmaker Sanofi SA and others joined the race to create a vaccine. A day after Geneva- based WHO declared an international public health emergency due to Zika's association with the birth defect microcephaly in...

  • LONDON, Feb 2- The world is once again asking scientists and drugmakers to come up rapidly with a vaccine for a viral disease that, in the latest case, few people had heard of until a few weeks ago, and even fewer feared. Making a shot to generate an immune response against Zika virus, which is sweeping through the Americas, shouldn't be too hard in theory.

  • PARIS/ LONDON, Feb 2- Sanofi has launched a project to develop a vaccine against the Zika virus in the most decisive commitment yet by a major vaccine producer to fight the disease linked to multiple birth defects in Brazil. The move comes a day after the World Health Organization declared the mosquito-borne Zika virus to be an international public health...

  • Jan 29- Companies and scientists are racing to create a Zika vaccine as concern grows over the mosquito-borne virus that has been linked to severe birth defects and is spreading quickly through the Americas. Brazil, the hardest-hit country, has reported around 3,700 cases of the devastating birth defect called microcephaly that are strongly suspected to be...

  • Jan 29- Drugmakers globally are racing to produce a vaccine for Zika, a mosquito-borne virus that has been linked to severe birth defects. The World Health Organization has warned the disease is spreading explosively through the Americas. But, companies and scientists have made clear that a vaccine for public use is, at the very least, some months away.

  • Jan 29- Privately owned vaccine developer Hawaii Biotech Inc has joined the race to produce a vaccine for the mosquito-borne Zika virus, a fast-spreading infection which has been linked to severe birth defects in babies. The company initiated a formal program to test a Zika vaccine last fall, as the virus began to gain traction in Brazil, said Chief Executive Dr.

  • Roche earnings miss forecasts

    Severin Schwan, CEO of Roche, discusses his company's full year results, which came in below expectations.

  • Health tech: UK vs USA

    The U.K. is becoming a test bed for developing and proving new digital technologies in health care says George Freeman MP, UK minister for life sciences, as he discusses health tech trends.

  • 2016 will be pivotal to health care: JP Morgan

    Cathrin Petty, head of EMEA healthcare at JP Morgan, says 2016 will be a pivotal year for the health care industry due to new product launches and approvals, as well as commercial headwinds.

  • The sun is shining on our sector: CEO

    Karl-Ludwig Kley, chairman and CEO of Merck, is positive about the prospects for the health care and life sciences sector.

  • We are prepared for the future: DSM CEO

    Feike Sijbesma, CEO of DSM, says the industry is changing the world transitions from fossil fuels to bio-renewable energy and discusses the economy in Europe and China.

  • Attention China: You can buy cans of clean Canadian air

    Harrison Wang, China spokesperson of Vitality Air, explains the concept behind the Canada-based company which sells cans of clean air.